Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Matrix Pharmaceutical (NasdaqNM:MATX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
34700 Campus Drive
Fremont, CA 94555
Phone: (510) 742-9900
Fax: (510) 742-8510
Email: investor_relations@matx.com
Employees (last reported count): 106
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 20%
·Over the last 6 months:
 · 2 insider buys; 4,000  shares
·Institutional: 53% (66% of float)
(111 institutions)
·Net Inst. Selling: 455.0K shares (+3.37%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Matrix Pharmaceutical, Inc. develops and manufactures novel drug product candidates for cancer based on its internal research and development capabilities and through in-licensing of product candidates from research institutions or other pharmaceutical companies. The Company's novel pharmaceutical product candidates are designed to improve the delivery of cancer drugs for more effective treatment of solid tumors. Two product candidates of the Company have been, or are being, evaluated in human clinical trials. These are IntraDose (cisplatin/epinephrine) Injectable Gel and MPI 5020 Radiopotentiator. The Company also in-licenses product candidates for development. In-licensed in 1998, tezacitabine (FMdC) is an intravenously administered therapeutic being developed for colorectal, hematologic and other cancers. The Company currently owns worldwide marketing rights for all its products under development, except for tezacitabine in Japan.
More from Market Guide: Expanded Business Description

Financial Summary
MATX is a development stage company engaged in the formulation and development of novel pharmaceutical product candidates that are designed to improve the delivery of cancer drugs to more effectively treat solid tumors. For the six months ended 6/30/01, revenues rose 66% to $715 thousand. Net loss increased 31% to $14.7 million. Revenues reflect an increased customer base. Net loss reflects increased S/G/A expenses due to higher marketing personnel costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Michael Casey, 55
Chairman, Pres and CEO
$711K--  
Richard Leavitt, M.D., 55
Sr. VP of Medical Affairs
315K$464K
Jeffrey Cooper, 45
VP-Fin.
--  --  
Ronald Lucas, 58
VP, Operations
252K31K
Jeanette Fritzky, 46
VP of Sales and Marketing
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:MATXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$6.00 
Recent Price$7.69 
52-Week High
on 18-Jan-2001
$17.375
Beta-0.35 
Daily Volume (3-month avg)142.1K
Daily Volume (10-day avg)393.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-49.6%
52-Week Change
relative to S&P500
-32.4%
Share-Related Items
Market Capitalization$202.2M
Shares Outstanding26.3M
Float21.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.31 
Earnings (ttm)-$1.04 
Earnings (mrq)-$0.31 
Sales (ttm)$0.07 
Cash (mrq)$1.57 
Valuation Ratios
Price/Book (mrq)5.86 
Price/EarningsN/A 
Price/Sales (ttm)108.54 
Income Statements
Sales (ttm)$1.82M
EBITDA (ttm)-$28.6M
Income available to common (ttm)-$26.8M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-43.29%
Return on Equity (ttm)-66.36%
Financial Strength
Current Ratio (mrq)6.96 
Debt/Equity (mrq)0.34 
Total Cash (mrq)$41.3M
Short Interest
As of 8-Aug-2001
Shares Short636.0K
Percent of Float3.0%
Shares Short
(Prior Month)
132.0K
Short Ratio5.39 
Daily Volume118.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.